Stock Market News
4D Pharma to trial biotherapeutic candidate in combination with Merck's 'KEYTRUDA'
Clinical stage biopharmaceutical company 4D Pharma announced an agreement with a subsidiary of Merck Sharp & Dohme (MSD) on Thursday, to conduct a clinical trial evaluating the combination of 'KEYTRUDA' (pembrolizumab) - an anti-PD-1 therapy marketed by MSD - and 4D's live biotherapeutic candidate MRx0518 in patients with solid tumours.
The AIM-traded firm said MRx0518, 4D's lead oncology programme, had shown therapeutic potential in a variety of tumour types in pre-clinical models, and had the potential for synergy in combination with checkpoint inhibitor therapies.
It said the phase I study would evaluate safety, tolerability and preliminary clinical benefit of the combination of KEYTRUDA with MRx0518 in patients who progressed on prior PD-1 inhibitor therapy with renal, bladder, melanoma and non-small cell lung cancer.
"At 4D we believe there is strong scientific rationale for evaluating our lead oncology programme MRx0518, in combination with a checkpoint inhibitor," said founder and CEO Duncan Peyton.
"We are excited to work with MSD and look forward to collaborating on this project."
The AIM-traded firm said MRx0518, 4D's lead oncology programme, had shown therapeutic potential in a variety of tumour types in pre-clinical models, and had the potential for synergy in combination with checkpoint inhibitor therapies.
It said the phase I study would evaluate safety, tolerability and preliminary clinical benefit of the combination of KEYTRUDA with MRx0518 in patients who progressed on prior PD-1 inhibitor therapy with renal, bladder, melanoma and non-small cell lung cancer.
"At 4D we believe there is strong scientific rationale for evaluating our lead oncology programme MRx0518, in combination with a checkpoint inhibitor," said founder and CEO Duncan Peyton.
"We are excited to work with MSD and look forward to collaborating on this project."
Related share prices |
---|
4D Pharma (DDDD) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price